Amicus Therapeutics (FOLD)

Executive Summary

Amicus Therapeutics is a global biotechnology company focused on developing transformative therapies for rare diseases, particularly lysosomal storage disorders. With a marketed product, Galafold (migalastat), for Fabry disease, the company generates steady revenue and is advancing a late-stage pipeline. Its most advanced candidate, cipaglucosidase alfa (AT-GAA) in combination with miglustat, is in a Phase 3 trial (PROPEL) for late-onset Pompe disease. Top-line data from this study is expected around mid-2026, representing a pivotal catalyst. If positive, Amicus could challenge Sanofi's Lumizyme with a potentially superior therapy. The company also has early-stage programs and explores next-generation enzyme replacement therapies. While commercial execution and pipeline progress are key, the upcoming Pompe data readout will significantly influence the stock's trajectory. Amicus maintains a strong balance sheet, with Galafold sales providing a foundation for growth.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 Pompe Disease (PROPEL) Top-Line Data65% success
• H2 2026Regulatory Filing Submission for Pompe Therapy (if data positive)60% success